Flagship Pioneering

Etiome is a biotechnology company that specializes in the development of innovative medicines, known as Biostaged Medicines. These medicines are designed to map and understand the progression of diseases with high resolution over time. Etiome's approach enables the healthcare industry to intervene at early stages of disease, preventing further progression and potentially halting debilitating and irreversible conditions.

Lila Sciences is a technology company that specializes in accelerating scientific research. It develops artificial intelligence-driven tools and autonomous labs, focusing on life sciences, chemical sciences, and materials sciences. The platform aims to enhance research efficiency and facilitate scientific discoveries by processing vast amounts of data, designing experiments, generating hypotheses, and testing them in real-world environments. This enables scientists to achieve breakthroughs and innovate more rapidly.

Mirai Bio is a biotechnology company that has created an AI-driven, open platform to overcome challenges in the development and manufacturing of genetic medicines. Their platform offers tools for biological and biomedical research, including data compilation, analysis algorithms, and scientific article search, focusing on DNA, RNA, and protein sequence analysis. This enables researchers to efficiently analyze data, derive insights from biological sequences, and accelerate their research progress.

Prologue Medicines creates transformative medicines by systematically discovering and evaluating viral proteins and their unique features.

Syros Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently in Phase II clinical trials for specific patient populations with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor under investigation in a Phase I clinical trial for advanced solid tumors. Syros is also engaged in collaborative research, including a partnership with Incyte Corporation aimed at identifying therapeutic targets for myeloproliferative neoplasms and a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. With a focus on mapping gene regulatory circuits, Syros leverages its proprietary platform and expertise to address significant unmet medical needs in oncology. Founded in 2011, the company aims to establish new standards of care for patients with hematologic malignancies.

Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapeutics through its pioneering platform in Generative Biology. Established in 2018, the company utilizes machine learning to analyze existing proteins, enabling it to understand the principles governing the relationship between genetic sequences and protein structure. This approach facilitates the invention of novel antibodies, peptides, enzymes, receptors, and other protein-based therapeutics optimized for specific biological functions. By harnessing its advanced technology, Generate Biomedicines aims to accelerate drug discovery by generating new biological molecules with significant therapeutic potential. Originally known as Generate Biologics, the company adopted its current name in March 2020 to reflect its expanded focus on biomedicine.

Empress Therapeutics is an early-stage biotechnology company focused on drug development and gaining new molecular insights into health and disease. The company utilizes a proprietary bio platform that integrates evolutionary principles, human molecular and genetic data, and artificial intelligence to identify advanced starting points in endogenous drug-like molecules. This innovative approach aims to enable clinicians to address a variety of serious unmet medical needs through the development of small-molecule drug candidates.

Ring Therapeutics is a biotechnology company developing gene therapies using Anellovector, a redosable and targetable DNA therapy platform based on the biology of the human commensal virome. The platform aims to address limitations of current DNA therapies, including limited tissue access, inability to redose, potential genomic integration, and tolerability concerns. Founded in 2017 and based in Cambridge, Massachusetts, Ring Therapeutics was established by Flagship Pioneering to pursue a multi-product platform. It focuses on discovering and developing Anellovector therapeutics to unlock the full potential of gene therapy, moving beyond gene replacement to a broader set of modalities and mechanisms. The approach targets disease sites with tissue and cellular specificity, aiming to treat conditions across genetic disorders, ophthalmology, oncology, and metabolic disorders and to expand therapeutic options for previously inaccessible diseases.

Montai harnesses digital technology and nature's power to treat and prevent chronic diseases. It pioneers Anthromolecule™ medications, derived from safe human-use compounds, aiming to improve health outcomes globally.

Cellarity is a therapeutics company that employs genomic technologies, data science, and artificial intelligence to develop medicines by digitizing and analyzing cellular molecular information and behaviors. The company's platform combines single-cell technologies with machine learning to quantify how cells behave in health and disease, map the network dynamics that govern those behaviors, and design medicines that direct them. Founded in 2017 and based in Cambridge, Massachusetts, Cellarity aims to advance drug discovery by targeting cellular and molecular complexity to improve the speed and success rate of therapies.

Senda Biosciences, founded in 2017 by David Kolesky, Ignacio Martinez, and John Casey in Cambridge, Massachusetts, focuses on developing therapeutic applications for innovative treatments of human diseases. The company specializes in studying the molecular relationships between bacterial, botanical, and human cells to understand how these interactions influence health and disease. By gaining insights into these interspecies connections, Senda Biosciences aims to create novel categories of medicines and delivery methods, providing medical professionals with new tools to combat various illnesses.

Tessera Therapeutics is an early-stage life sciences company focused on pioneering Gene Writing technology, which allows for the precise insertion of therapeutic messages into the human genome. This innovative approach aims to address diseases at their source by enabling both small and large genetic alterations. By building on recent advancements in gene therapy and gene editing, Tessera Therapeutics seeks to overcome existing limitations in these fields, enhancing their efficacy and reach. Founded by Flagship Pioneering, the company aspires to establish a new category in genetic medicine that can significantly improve patient outcomes and transform healthcare.

Vesalius Therapeutics is a biotechnology company dedicated to advancing the understanding and treatment of diseases responsible for the majority of human illnesses. The company has developed a platform that connects clinical patterns with the interactions of various genes, allowing for the identification of genetic circuits that contribute to disease. By creating proprietary, patient-derived, cell-based experimental models, Vesalius Therapeutics screens and characterizes drug candidates aimed at restoring the functionality of these genetic circuits. This innovative approach empowers healthcare practitioners to identify previously unrecognized clinical patterns among patient populations, ultimately enhancing the potential for targeted and effective treatments.

Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapeutics through its pioneering platform in Generative Biology. Established in 2018, the company utilizes machine learning to analyze existing proteins, enabling it to understand the principles governing the relationship between genetic sequences and protein structure. This approach facilitates the invention of novel antibodies, peptides, enzymes, receptors, and other protein-based therapeutics optimized for specific biological functions. By harnessing its advanced technology, Generate Biomedicines aims to accelerate drug discovery by generating new biological molecules with significant therapeutic potential. Originally known as Generate Biologics, the company adopted its current name in March 2020 to reflect its expanded focus on biomedicine.

Laronde is a biotechnology company that specializes in developing an eRNA-based therapeutic platform designed to express a variety of proteins within the body. Founded in 2017 by Flagship Labs, Laronde's innovative Endless RNA technology is engineered to be persistent and non-immunogenic, allowing for repeat dosing and offering flexibility in both formulation and delivery. This platform aims to enhance the predictability and efficacy of new medicines, facilitating the development of therapeutics that can address a wide range of diseases. As Laronde continues to scale its operations, it focuses on advancing multiple programs simultaneously, positioning itself as a key player in the future of medicine.

Ring Therapeutics is a biotechnology company developing gene therapies using Anellovector, a redosable and targetable DNA therapy platform based on the biology of the human commensal virome. The platform aims to address limitations of current DNA therapies, including limited tissue access, inability to redose, potential genomic integration, and tolerability concerns. Founded in 2017 and based in Cambridge, Massachusetts, Ring Therapeutics was established by Flagship Pioneering to pursue a multi-product platform. It focuses on discovering and developing Anellovector therapeutics to unlock the full potential of gene therapy, moving beyond gene replacement to a broader set of modalities and mechanisms. The approach targets disease sites with tissue and cellular specificity, aiming to treat conditions across genetic disorders, ophthalmology, oncology, and metabolic disorders and to expand therapeutic options for previously inaccessible diseases.

Laronde is a biotechnology company that specializes in developing an eRNA-based therapeutic platform designed to express a variety of proteins within the body. Founded in 2017 by Flagship Labs, Laronde's innovative Endless RNA technology is engineered to be persistent and non-immunogenic, allowing for repeat dosing and offering flexibility in both formulation and delivery. This platform aims to enhance the predictability and efficacy of new medicines, facilitating the development of therapeutics that can address a wide range of diseases. As Laronde continues to scale its operations, it focuses on advancing multiple programs simultaneously, positioning itself as a key player in the future of medicine.

Cellarity is a therapeutics company that employs genomic technologies, data science, and artificial intelligence to develop medicines by digitizing and analyzing cellular molecular information and behaviors. The company's platform combines single-cell technologies with machine learning to quantify how cells behave in health and disease, map the network dynamics that govern those behaviors, and design medicines that direct them. Founded in 2017 and based in Cambridge, Massachusetts, Cellarity aims to advance drug discovery by targeting cellular and molecular complexity to improve the speed and success rate of therapies.

Tessera Therapeutics is an early-stage life sciences company focused on pioneering Gene Writing technology, which allows for the precise insertion of therapeutic messages into the human genome. This innovative approach aims to address diseases at their source by enabling both small and large genetic alterations. By building on recent advancements in gene therapy and gene editing, Tessera Therapeutics seeks to overcome existing limitations in these fields, enhancing their efficacy and reach. Founded by Flagship Pioneering, the company aspires to establish a new category in genetic medicine that can significantly improve patient outcomes and transform healthcare.

Valo Health is a technology company focused on transforming the drug discovery and development process through the integration of human and machine intelligence. By leveraging machine learning, cloud computing, and extensive data analysis, Valo Health's platform facilitates the identification of previously unknown connections between genetic markers and diseases. This human-centric approach supports clients in the healthcare sector in the development of treatments for various conditions, including oncology, neurodegenerative diseases, and cardiovascular issues. Through its innovative platform, Valo Health aims to accelerate the creation of impactful therapies.

Senda Biosciences, founded in 2017 by David Kolesky, Ignacio Martinez, and John Casey in Cambridge, Massachusetts, focuses on developing therapeutic applications for innovative treatments of human diseases. The company specializes in studying the molecular relationships between bacterial, botanical, and human cells to understand how these interactions influence health and disease. By gaining insights into these interspecies connections, Senda Biosciences aims to create novel categories of medicines and delivery methods, providing medical professionals with new tools to combat various illnesses.

Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapeutics through its pioneering platform in Generative Biology. Established in 2018, the company utilizes machine learning to analyze existing proteins, enabling it to understand the principles governing the relationship between genetic sequences and protein structure. This approach facilitates the invention of novel antibodies, peptides, enzymes, receptors, and other protein-based therapeutics optimized for specific biological functions. By harnessing its advanced technology, Generate Biomedicines aims to accelerate drug discovery by generating new biological molecules with significant therapeutic potential. Originally known as Generate Biologics, the company adopted its current name in March 2020 to reflect its expanded focus on biomedicine.

Founded in 2018, Sana Biotechnology focuses on creating and delivering engineered cells as medicine for patients. The company aims to reprogram cells in the body or replace damaged ones to treat a broad range of diseases, with a pipeline including SC291, SC262, SC255, UP421, and other candidates across therapeutic areas like oncology, diabetes, autoimmune disorders, and CNS.

Sigilon Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing functional cures for patients with chronic diseases. Founded in 2015, the company aims to create immune-protected, engineered human cells that restore normal physiological functions without the risk of fibrosis or immune rejection. Its lead product candidate, SIG-001, is currently in Phase I/II clinical trials for preventing bleeding episodes in patients with moderate to severe Hemophilia A. Additionally, Sigilon is advancing other candidates, including SIG-005, which targets non-neurological manifestations of mucopolysaccharidosis type 1, and SIG-002, designed to replace islet cells for treating type 1 diabetes. The company's innovative Shielded Living Therapeutics platform leverages advances in cell engineering and proprietary biocompatible materials to offer stable and durable therapeutic solutions for a variety of chronic conditions.

Ring Therapeutics is a biotechnology company developing gene therapies using Anellovector, a redosable and targetable DNA therapy platform based on the biology of the human commensal virome. The platform aims to address limitations of current DNA therapies, including limited tissue access, inability to redose, potential genomic integration, and tolerability concerns. Founded in 2017 and based in Cambridge, Massachusetts, Ring Therapeutics was established by Flagship Pioneering to pursue a multi-product platform. It focuses on discovering and developing Anellovector therapeutics to unlock the full potential of gene therapy, moving beyond gene replacement to a broader set of modalities and mechanisms. The approach targets disease sites with tissue and cellular specificity, aiming to treat conditions across genetic disorders, ophthalmology, oncology, and metabolic disorders and to expand therapeutic options for previously inaccessible diseases.

Cellarity is a therapeutics company that employs genomic technologies, data science, and artificial intelligence to develop medicines by digitizing and analyzing cellular molecular information and behaviors. The company's platform combines single-cell technologies with machine learning to quantify how cells behave in health and disease, map the network dynamics that govern those behaviors, and design medicines that direct them. Founded in 2017 and based in Cambridge, Massachusetts, Cellarity aims to advance drug discovery by targeting cellular and molecular complexity to improve the speed and success rate of therapies.

Cygnal Therapeutics, established in 2016 in Cambridge, Massachusetts, specializes in developing drugs that target and manipulate exoneural biology for treating cancer, immunological diseases, and regenerative processes. The company leverages a state-of-the-art neurotechnology platform to uncover novel aspects of neural function, enabling innovative therapeutic approaches. Cygnal was founded by Flagship Pioneering through its VentureLabs innovation foundry.

Valo Health is a technology company focused on transforming the drug discovery and development process through the integration of human and machine intelligence. By leveraging machine learning, cloud computing, and extensive data analysis, Valo Health's platform facilitates the identification of previously unknown connections between genetic markers and diseases. This human-centric approach supports clients in the healthcare sector in the development of treatments for various conditions, including oncology, neurodegenerative diseases, and cardiovascular issues. Through its innovative platform, Valo Health aims to accelerate the creation of impactful therapies.

Founded in 2018, Sana Biotechnology focuses on creating and delivering engineered cells as medicine for patients. The company aims to reprogram cells in the body or replace damaged ones to treat a broad range of diseases, with a pipeline including SC291, SC262, SC255, UP421, and other candidates across therapeutic areas like oncology, diabetes, autoimmune disorders, and CNS.

Axcella Health Inc., established in 2008 and headquartered in Cambridge, Massachusetts, is a clinical-stage biotechnology company. It specializes in developing endogenous metabolic modulators (EMMs) to treat complex diseases. Axcella's proprietary platform combines systems biology and machine learning to identify and validate EMM compositions. The company has clinical-stage candidates targeting muscle, neurodegenerative, and liver conditions, including AXA1665 for hepatic encephalopathy and AXA1125 for non-alcoholic steatohepatitis.

Kaleido Biosciences is a clinical-stage healthcare company dedicated to harnessing the potential of the microbiome to treat diseases and enhance human health. The company has developed a proprietary product platform that enables the rapid and cost-effective discovery of Microbiome Metabolic Therapies (MMTs). These therapies aim to modulate the metabolic output and profile of the microbiome by influencing the function and distribution of its existing microbes. Kaleido is advancing a diverse pipeline of MMT candidates that target various diseases and conditions, addressing significant unmet medical needs.

Codiak BioSciences is a clinical-stage biopharmaceutical company dedicated to developing exosome-based therapeutics, a novel class of medicines with the potential to address various diseases with significant unmet medical needs. The company employs its proprietary engEx Platform, which allows for the engineering and manufacturing of exosomes, leveraging their natural role as intercellular messengers. Codiak's pipeline includes product candidates such as exoSTING and exoIL-12, targeting diverse therapeutic areas including oncology, neuro-oncology, neurology, neuromuscular diseases, and infectious diseases. Additionally, the company collaborates with the Ragon Institute to explore the potential of its exoVACC platform for vaccines against SARS-CoV-2 and HIV. Founded in 2015 and headquartered in Cambridge, Massachusetts, Codiak aims to transform therapeutic approaches by harnessing the unique properties of exosomes.

Kaleido Biosciences is a clinical-stage healthcare company dedicated to harnessing the potential of the microbiome to treat diseases and enhance human health. The company has developed a proprietary product platform that enables the rapid and cost-effective discovery of Microbiome Metabolic Therapies (MMTs). These therapies aim to modulate the metabolic output and profile of the microbiome by influencing the function and distribution of its existing microbes. Kaleido is advancing a diverse pipeline of MMT candidates that target various diseases and conditions, addressing significant unmet medical needs.

Tarveda Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies aimed at addressing the complexities of treating solid tumors. Founded in 2011 and based in Watertown, Massachusetts, the company specializes in miniature drug conjugates. Its lead candidate, PEN-866, utilizes a platform that targets the activated form of Heat Shock Protein 90 (HSP90) in tumors, delivering a potent topoisomerase 1 inhibitor payload, SN38. Additionally, Tarveda is evaluating another miniature drug conjugate designed for patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors, small cell lung cancer, and other solid tumors. Through its targeted approach, Tarveda seeks to extend the lives of patients facing challenging cancers while minimizing potential toxicities associated with treatment.

Codiak BioSciences is a clinical-stage biopharmaceutical company dedicated to developing exosome-based therapeutics, a novel class of medicines with the potential to address various diseases with significant unmet medical needs. The company employs its proprietary engEx Platform, which allows for the engineering and manufacturing of exosomes, leveraging their natural role as intercellular messengers. Codiak's pipeline includes product candidates such as exoSTING and exoIL-12, targeting diverse therapeutic areas including oncology, neuro-oncology, neurology, neuromuscular diseases, and infectious diseases. Additionally, the company collaborates with the Ragon Institute to explore the potential of its exoVACC platform for vaccines against SARS-CoV-2 and HIV. Founded in 2015 and headquartered in Cambridge, Massachusetts, Codiak aims to transform therapeutic approaches by harnessing the unique properties of exosomes.

Codiak BioSciences is a clinical-stage biopharmaceutical company dedicated to developing exosome-based therapeutics, a novel class of medicines with the potential to address various diseases with significant unmet medical needs. The company employs its proprietary engEx Platform, which allows for the engineering and manufacturing of exosomes, leveraging their natural role as intercellular messengers. Codiak's pipeline includes product candidates such as exoSTING and exoIL-12, targeting diverse therapeutic areas including oncology, neuro-oncology, neurology, neuromuscular diseases, and infectious diseases. Additionally, the company collaborates with the Ragon Institute to explore the potential of its exoVACC platform for vaccines against SARS-CoV-2 and HIV. Founded in 2015 and headquartered in Cambridge, Massachusetts, Codiak aims to transform therapeutic approaches by harnessing the unique properties of exosomes.

Editas Medicine is a clinical-stage biotechnology company based in Cambridge, Massachusetts, with an additional site in Boulder, Colorado. Founded in 2013, the company focuses on the discovery and development of genome editing therapeutics, primarily utilizing its proprietary CRISPR/Cas9 technology. This innovative platform enables precise molecular modifications at the genetic level, with the aim of treating a wide array of serious diseases by addressing their underlying causes. Editas Medicine has established a strong intellectual property portfolio, which includes numerous patents related to foundational genome editing technologies and advancements that facilitate the translation of research into viable human therapeutics. The company's mission is to pioneer transformative genomic medicines that can significantly improve patient outcomes across various genetic disorders.

Axcella Health Inc., established in 2008 and headquartered in Cambridge, Massachusetts, is a clinical-stage biotechnology company. It specializes in developing endogenous metabolic modulators (EMMs) to treat complex diseases. Axcella's proprietary platform combines systems biology and machine learning to identify and validate EMM compositions. The company has clinical-stage candidates targeting muscle, neurodegenerative, and liver conditions, including AXA1665 for hepatic encephalopathy and AXA1125 for non-alcoholic steatohepatitis.

Tarveda Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies aimed at addressing the complexities of treating solid tumors. Founded in 2011 and based in Watertown, Massachusetts, the company specializes in miniature drug conjugates. Its lead candidate, PEN-866, utilizes a platform that targets the activated form of Heat Shock Protein 90 (HSP90) in tumors, delivering a potent topoisomerase 1 inhibitor payload, SN38. Additionally, Tarveda is evaluating another miniature drug conjugate designed for patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors, small cell lung cancer, and other solid tumors. Through its targeted approach, Tarveda seeks to extend the lives of patients facing challenging cancers while minimizing potential toxicities associated with treatment.

Seres Therapeutics is a clinical-stage biotherapeutic company based in Cambridge, Massachusetts, specializing in the development of microbiome therapeutics aimed at restoring health by correcting dysbiotic microbiomes. The company's lead product candidate, SER-109, is currently in Phase III clinical trials for the prevention of recurrent Clostridium difficile infection (CDI). In addition to SER-109, Seres is advancing several other therapeutic candidates: SER-287, which is in a Phase IIb study for ulcerative colitis; SER-401, a microbiome therapeutic in a Phase Ib study for use with checkpoint inhibitors in metastatic melanoma; SER-301 for inflammatory bowel disease; SER-262 for initial CDI recurrence; and SER-155 to address dysbiosis post-allogeneic hematopoietic stem cell transplants. Seres Therapeutics collaborates with notable institutions such as Nestec Ltd. and Memorial Sloan Kettering Cancer Center, and has partnered with AstraZeneca to enhance its research and development efforts. Founded in 2010, Seres Therapeutics was previously known as Seres Health, Inc. until its name change in May 2015.

Syros Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently in Phase II clinical trials for specific patient populations with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor under investigation in a Phase I clinical trial for advanced solid tumors. Syros is also engaged in collaborative research, including a partnership with Incyte Corporation aimed at identifying therapeutic targets for myeloproliferative neoplasms and a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. With a focus on mapping gene regulatory circuits, Syros leverages its proprietary platform and expertise to address significant unmet medical needs in oncology. Founded in 2011, the company aims to establish new standards of care for patients with hematologic malignancies.

Seres Therapeutics is a clinical-stage biotherapeutic company based in Cambridge, Massachusetts, specializing in the development of microbiome therapeutics aimed at restoring health by correcting dysbiotic microbiomes. The company's lead product candidate, SER-109, is currently in Phase III clinical trials for the prevention of recurrent Clostridium difficile infection (CDI). In addition to SER-109, Seres is advancing several other therapeutic candidates: SER-287, which is in a Phase IIb study for ulcerative colitis; SER-401, a microbiome therapeutic in a Phase Ib study for use with checkpoint inhibitors in metastatic melanoma; SER-301 for inflammatory bowel disease; SER-262 for initial CDI recurrence; and SER-155 to address dysbiosis post-allogeneic hematopoietic stem cell transplants. Seres Therapeutics collaborates with notable institutions such as Nestec Ltd. and Memorial Sloan Kettering Cancer Center, and has partnered with AstraZeneca to enhance its research and development efforts. Founded in 2010, Seres Therapeutics was previously known as Seres Health, Inc. until its name change in May 2015.

Tarveda Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies aimed at addressing the complexities of treating solid tumors. Founded in 2011 and based in Watertown, Massachusetts, the company specializes in miniature drug conjugates. Its lead candidate, PEN-866, utilizes a platform that targets the activated form of Heat Shock Protein 90 (HSP90) in tumors, delivering a potent topoisomerase 1 inhibitor payload, SN38. Additionally, Tarveda is evaluating another miniature drug conjugate designed for patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors, small cell lung cancer, and other solid tumors. Through its targeted approach, Tarveda seeks to extend the lives of patients facing challenging cancers while minimizing potential toxicities associated with treatment.

Axcella Health Inc., established in 2008 and headquartered in Cambridge, Massachusetts, is a clinical-stage biotechnology company. It specializes in developing endogenous metabolic modulators (EMMs) to treat complex diseases. Axcella's proprietary platform combines systems biology and machine learning to identify and validate EMM compositions. The company has clinical-stage candidates targeting muscle, neurodegenerative, and liver conditions, including AXA1665 for hepatic encephalopathy and AXA1125 for non-alcoholic steatohepatitis.

Editas Medicine is a clinical-stage biotechnology company based in Cambridge, Massachusetts, with an additional site in Boulder, Colorado. Founded in 2013, the company focuses on the discovery and development of genome editing therapeutics, primarily utilizing its proprietary CRISPR/Cas9 technology. This innovative platform enables precise molecular modifications at the genetic level, with the aim of treating a wide array of serious diseases by addressing their underlying causes. Editas Medicine has established a strong intellectual property portfolio, which includes numerous patents related to foundational genome editing technologies and advancements that facilitate the translation of research into viable human therapeutics. The company's mission is to pioneer transformative genomic medicines that can significantly improve patient outcomes across various genetic disorders.

Axcella Health Inc., established in 2008 and headquartered in Cambridge, Massachusetts, is a clinical-stage biotechnology company. It specializes in developing endogenous metabolic modulators (EMMs) to treat complex diseases. Axcella's proprietary platform combines systems biology and machine learning to identify and validate EMM compositions. The company has clinical-stage candidates targeting muscle, neurodegenerative, and liver conditions, including AXA1665 for hepatic encephalopathy and AXA1125 for non-alcoholic steatohepatitis.

Syros Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently in Phase II clinical trials for specific patient populations with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor under investigation in a Phase I clinical trial for advanced solid tumors. Syros is also engaged in collaborative research, including a partnership with Incyte Corporation aimed at identifying therapeutic targets for myeloproliferative neoplasms and a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. With a focus on mapping gene regulatory circuits, Syros leverages its proprietary platform and expertise to address significant unmet medical needs in oncology. Founded in 2011, the company aims to establish new standards of care for patients with hematologic malignancies.

T2 Biosystems, Inc. is an in vitro diagnostics company specializing in the rapid detection of pathogens and biomarkers to enhance patient care. The company employs its proprietary T2 Magnetic Resonance technology, which allows for the detection of various pathogens directly from unpurified patient samples, such as whole blood and urine, without the need for extensive sample preparation. T2 Biosystems offers several diagnostic products, including the T2Dx Instrument, which is designed to identify pathogens associated with sepsis and Lyme disease. Its product lineup includes the T2Candida Panel for detecting Candida species, the T2Bacteria Panel for identifying bacterial pathogens, the T2SARS-CoV-2 Panel for COVID-19 testing, and the T2Resistance Panel for detecting antibiotic resistance markers. Founded in 2006 and headquartered in Lexington, Massachusetts, T2 Biosystems aims to improve clinical outcomes and reduce healthcare costs by enabling faster and more accurate diagnostic testing.

Seres Therapeutics is a clinical-stage biotherapeutic company based in Cambridge, Massachusetts, specializing in the development of microbiome therapeutics aimed at restoring health by correcting dysbiotic microbiomes. The company's lead product candidate, SER-109, is currently in Phase III clinical trials for the prevention of recurrent Clostridium difficile infection (CDI). In addition to SER-109, Seres is advancing several other therapeutic candidates: SER-287, which is in a Phase IIb study for ulcerative colitis; SER-401, a microbiome therapeutic in a Phase Ib study for use with checkpoint inhibitors in metastatic melanoma; SER-301 for inflammatory bowel disease; SER-262 for initial CDI recurrence; and SER-155 to address dysbiosis post-allogeneic hematopoietic stem cell transplants. Seres Therapeutics collaborates with notable institutions such as Nestec Ltd. and Memorial Sloan Kettering Cancer Center, and has partnered with AstraZeneca to enhance its research and development efforts. Founded in 2010, Seres Therapeutics was previously known as Seres Health, Inc. until its name change in May 2015.

Quanterix is a life sciences company that develops an ultra-sensitive digital immunoassay platform to advance precision health for research and diagnostics. Its Simoa platform employs bead-based and planar array technologies to detect protein biomarkers at very low concentrations in blood, serum, and other fluids that are undetectable by conventional assays. This enables early disease detection, improved prognosis, and more informed treatment decisions in clinical settings and research. The company provides instruments, assay kits, LDTs and assay services, as well as specialized modules and systems such as HD-X automated immunoassay analyzer, aiming to support biomarker analysis across healthcare and life science applications.

Sesen Bio, Inc. is a late-stage clinical company based in Cambridge, Massachusetts, that focuses on the design, development, and commercialization of targeted fusion protein therapeutics for cancer treatment. The company's lead product candidate, Vicinium, is a locally-administered therapy currently in phase 3 clinical trials aimed at treating high-risk non-muscle invasive bladder cancer. Additionally, Sesen Bio is developing VB6-845d, a systemically-administered product for various EpCAM-positive solid tumors. The company is also exploring combination therapies, including Vicinium with Durvalumab for high-risk non-muscle invasive bladder cancer and another combination for squamous cell carcinoma of the head and neck. Sesen Bio has partnered with Leiden University Medical Center to co-develop an imaging agent. Established in 2008 and previously known as Eleven Biotherapeutics, Sesen Bio has developed a proprietary platform that combines antibody fragments with cytotoxic proteins to create innovative therapies.

Helicos BioSciences Corporation (Helicos) is a life sciences company, which has developed technology focused on the research, drug discovery and clinical diagnostics markets. Its True Single Molecule Sequencing (tSMS) technology enables rapid analysis of large quantities of genetic material by directly sequencing single molecules of deoxyribonucleic acid (DNA) or single DNA copies of ribonucleic acid (RNA) (cDNA) and its approach of direct sequencing of RNA. Its Helicos Genetic Analysis Platform is designed to obtain sequencing information by repetitively performing a cycle of biochemical reactions on individual DNA or RNA molecules and imaging the results after each cycle. The platform consists of an instrument called the HeliScope Single Molecule Sequencer, an image analysis computer tower called the HeliScope Analysis Engine, associated reagents, which are chemicals used in the sequencing process and disposable supplies.

Tarveda Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies aimed at addressing the complexities of treating solid tumors. Founded in 2011 and based in Watertown, Massachusetts, the company specializes in miniature drug conjugates. Its lead candidate, PEN-866, utilizes a platform that targets the activated form of Heat Shock Protein 90 (HSP90) in tumors, delivering a potent topoisomerase 1 inhibitor payload, SN38. Additionally, Tarveda is evaluating another miniature drug conjugate designed for patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors, small cell lung cancer, and other solid tumors. Through its targeted approach, Tarveda seeks to extend the lives of patients facing challenging cancers while minimizing potential toxicities associated with treatment.

Permeon Biologics is a biotechnology company focused on developing a new generation of therapeutic drugs designed to enhance human health. Utilizing its proprietary Intraphilin Technology Platform, the company identifies naturally occurring human proteins with enhanced capabilities to facilitate intracellular delivery. This technology enables functional proteins to effectively replace or restore defective cellular pathways responsible for various diseases. By leveraging these "supercharged proteins," Permeon Biologics aims to create innovative biologic therapies that address significant medical needs.

Agios Pharmaceuticals is a biopharmaceutical company focused on developing targeted therapies in the field of cellular metabolism. It discovers and develops medicines for various indications, including hematologic malignancies, solid tumors, and rare genetic diseases.

T2 Biosystems, Inc. is an in vitro diagnostics company specializing in the rapid detection of pathogens and biomarkers to enhance patient care. The company employs its proprietary T2 Magnetic Resonance technology, which allows for the detection of various pathogens directly from unpurified patient samples, such as whole blood and urine, without the need for extensive sample preparation. T2 Biosystems offers several diagnostic products, including the T2Dx Instrument, which is designed to identify pathogens associated with sepsis and Lyme disease. Its product lineup includes the T2Candida Panel for detecting Candida species, the T2Bacteria Panel for identifying bacterial pathogens, the T2SARS-CoV-2 Panel for COVID-19 testing, and the T2Resistance Panel for detecting antibiotic resistance markers. Founded in 2006 and headquartered in Lexington, Massachusetts, T2 Biosystems aims to improve clinical outcomes and reduce healthcare costs by enabling faster and more accurate diagnostic testing.

LS9, known as the Renewable Petroleum Company, is a privately-held industrial biotechnology firm based in South San Francisco, California. The company focuses on the development and production of patent-pending UltraClean fuels and sustainable chemicals utilizing synthetic biology. By harnessing advanced industrial synthetic biology techniques, LS9 aims to create renewable petroleum biofuels that serve as eco-friendly alternatives to traditional fossil fuels.

BIND Therapeutics is a clinical-stage nanomedicine platform company focused on developing innovative targeted and programmable therapeutics known as Accurins. These specialized drug delivery systems are engineered with distinct physical and chemical properties to effectively target specific cells or tissues, concentrating therapeutic agents at the disease site to improve treatment efficacy while reducing adverse effects on healthy tissues. BIND's primary focus is on oncology, with its lead drug candidate, BIND-014, currently undergoing Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer. The company also collaborates with leading biopharmaceutical firms, such as Amgen, Pfizer, and AstraZeneca, to create Accurins utilizing their therapeutic payloads. Through its medicinal nanoengineering platform, BIND Therapeutics aims to advance its own pipeline and forge strategic partnerships in the field of cancer treatment.

Tetraphase Pharmaceuticals, Inc. is a biopharmaceutical company focused on the creation, development, and commercialization of innovative antibiotics aimed at treating serious and life-threatening multidrug-resistant infections. The company's primary product, Xerava, is a synthetic fluorocycline administered intravenously, designed as a first-line empiric monotherapy for multidrug-resistant infections, particularly those caused by MDR Gram-negative bacteria. Tetraphase has successfully conducted Phase III clinical trials for Xerava, specifically targeting complicated intra-abdominal infections. In addition to Xerava, the company is developing several other candidates, including TP-271 for respiratory diseases linked to bacterial biothreats and TP-6076 for MDR Gram-negative infections, both in Phase I clinical trials. Furthermore, TP-2846 is being explored as a treatment for acute myeloid leukemia. Tetraphase Pharmaceuticals has established a licensing agreement with Everest Medicines Limited to enhance the development and commercialization of Xerava in select regions across Asia. Founded in 2006 and headquartered in Watertown, Massachusetts, Tetraphase operates as a subsidiary of La Jolla Pharmaceutical Company.

T2 Biosystems, Inc. is an in vitro diagnostics company specializing in the rapid detection of pathogens and biomarkers to enhance patient care. The company employs its proprietary T2 Magnetic Resonance technology, which allows for the detection of various pathogens directly from unpurified patient samples, such as whole blood and urine, without the need for extensive sample preparation. T2 Biosystems offers several diagnostic products, including the T2Dx Instrument, which is designed to identify pathogens associated with sepsis and Lyme disease. Its product lineup includes the T2Candida Panel for detecting Candida species, the T2Bacteria Panel for identifying bacterial pathogens, the T2SARS-CoV-2 Panel for COVID-19 testing, and the T2Resistance Panel for detecting antibiotic resistance markers. Founded in 2006 and headquartered in Lexington, Massachusetts, T2 Biosystems aims to improve clinical outcomes and reduce healthcare costs by enabling faster and more accurate diagnostic testing.

Sesen Bio, Inc. is a late-stage clinical company based in Cambridge, Massachusetts, that focuses on the design, development, and commercialization of targeted fusion protein therapeutics for cancer treatment. The company's lead product candidate, Vicinium, is a locally-administered therapy currently in phase 3 clinical trials aimed at treating high-risk non-muscle invasive bladder cancer. Additionally, Sesen Bio is developing VB6-845d, a systemically-administered product for various EpCAM-positive solid tumors. The company is also exploring combination therapies, including Vicinium with Durvalumab for high-risk non-muscle invasive bladder cancer and another combination for squamous cell carcinoma of the head and neck. Sesen Bio has partnered with Leiden University Medical Center to co-develop an imaging agent. Established in 2008 and previously known as Eleven Biotherapeutics, Sesen Bio has developed a proprietary platform that combines antibody fragments with cytotoxic proteins to create innovative therapies.

LS9, known as the Renewable Petroleum Company, is a privately-held industrial biotechnology firm based in South San Francisco, California. The company focuses on the development and production of patent-pending UltraClean fuels and sustainable chemicals utilizing synthetic biology. By harnessing advanced industrial synthetic biology techniques, LS9 aims to create renewable petroleum biofuels that serve as eco-friendly alternatives to traditional fossil fuels.

Helicos BioSciences Corporation (Helicos) is a life sciences company, which has developed technology focused on the research, drug discovery and clinical diagnostics markets. Its True Single Molecule Sequencing (tSMS) technology enables rapid analysis of large quantities of genetic material by directly sequencing single molecules of deoxyribonucleic acid (DNA) or single DNA copies of ribonucleic acid (RNA) (cDNA) and its approach of direct sequencing of RNA. Its Helicos Genetic Analysis Platform is designed to obtain sequencing information by repetitively performing a cycle of biochemical reactions on individual DNA or RNA molecules and imaging the results after each cycle. The platform consists of an instrument called the HeliScope Single Molecule Sequencer, an image analysis computer tower called the HeliScope Analysis Engine, associated reagents, which are chemicals used in the sequencing process and disposable supplies.

Tetraphase Pharmaceuticals, Inc. is a biopharmaceutical company focused on the creation, development, and commercialization of innovative antibiotics aimed at treating serious and life-threatening multidrug-resistant infections. The company's primary product, Xerava, is a synthetic fluorocycline administered intravenously, designed as a first-line empiric monotherapy for multidrug-resistant infections, particularly those caused by MDR Gram-negative bacteria. Tetraphase has successfully conducted Phase III clinical trials for Xerava, specifically targeting complicated intra-abdominal infections. In addition to Xerava, the company is developing several other candidates, including TP-271 for respiratory diseases linked to bacterial biothreats and TP-6076 for MDR Gram-negative infections, both in Phase I clinical trials. Furthermore, TP-2846 is being explored as a treatment for acute myeloid leukemia. Tetraphase Pharmaceuticals has established a licensing agreement with Everest Medicines Limited to enhance the development and commercialization of Xerava in select regions across Asia. Founded in 2006 and headquartered in Watertown, Massachusetts, Tetraphase operates as a subsidiary of La Jolla Pharmaceutical Company.

Alvine Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing biologics for autoimmune and inflammatory diseases, with a particular emphasis on celiac disease. The company's lead product, ALV003, is an orally administered mixture of two gluten-specific proteases designed to degrade gluten, the primary immunologic trigger for celiac disease. In addition to ALV003, Alvine is also developing other proteases that target celiac disease, including Transglutaminase 2 (TG2) and the HLADQ2 heterodimer. Founded in 2005 and based in San Carlos, California, Alvine Pharmaceuticals operates as a subsidiary of ImmunogenX, LLC.

Pervasis Therapeutics is a clinical stage biotechnology company focused on developing innovative biologically active therapeutics aimed at enhancing healing and repair processes associated with various diseases. Leveraging its expertise in endothelial biology, the company is advancing novel therapies designed to improve outcomes in common vascular interventions, including arteriovenous access, angioplasties, stents, and bypass grafts. These interventions are critical, as their failure can lead to severe complications and increased healthcare costs. One of the company's key products, PVS-30200, is a matrix-embedded endothelial cell-based therapy that targets and regulates cell stroma, aiming to address vascular injuries across diverse clinical settings. Through its research and development efforts, Pervasis Therapeutics seeks to transform the treatment landscape for serious illnesses related to vascular health.

Seahorse Bioscience specializes in providing analytical instruments, biomanufacturing systems, and consumable labware for biological research and drug discovery. The company is known for its Seahorse extracellular flux (XF) analyzers, which allow for non-invasive profiling of cellular metabolic activity. These instruments enable researchers to assess key metabolic parameters, such as basal oxygen consumption, glycolysis rates, ATP turnover, and respiratory capacity, thereby facilitating the study of mitochondrial dysfunction. Seahorse Bioscience serves a diverse clientele, including scientists at academic institutions, pharmaceutical and biotech companies, and original equipment manufacturers of assay kits and laboratory instruments.

T2 Biosystems, Inc. is an in vitro diagnostics company specializing in the rapid detection of pathogens and biomarkers to enhance patient care. The company employs its proprietary T2 Magnetic Resonance technology, which allows for the detection of various pathogens directly from unpurified patient samples, such as whole blood and urine, without the need for extensive sample preparation. T2 Biosystems offers several diagnostic products, including the T2Dx Instrument, which is designed to identify pathogens associated with sepsis and Lyme disease. Its product lineup includes the T2Candida Panel for detecting Candida species, the T2Bacteria Panel for identifying bacterial pathogens, the T2SARS-CoV-2 Panel for COVID-19 testing, and the T2Resistance Panel for detecting antibiotic resistance markers. Founded in 2006 and headquartered in Lexington, Massachusetts, T2 Biosystems aims to improve clinical outcomes and reduce healthcare costs by enabling faster and more accurate diagnostic testing.

Quanterix is a life sciences company that develops an ultra-sensitive digital immunoassay platform to advance precision health for research and diagnostics. Its Simoa platform employs bead-based and planar array technologies to detect protein biomarkers at very low concentrations in blood, serum, and other fluids that are undetectable by conventional assays. This enables early disease detection, improved prognosis, and more informed treatment decisions in clinical settings and research. The company provides instruments, assay kits, LDTs and assay services, as well as specialized modules and systems such as HD-X automated immunoassay analyzer, aiming to support biomarker analysis across healthcare and life science applications.

Tetraphase Pharmaceuticals, Inc. is a biopharmaceutical company focused on the creation, development, and commercialization of innovative antibiotics aimed at treating serious and life-threatening multidrug-resistant infections. The company's primary product, Xerava, is a synthetic fluorocycline administered intravenously, designed as a first-line empiric monotherapy for multidrug-resistant infections, particularly those caused by MDR Gram-negative bacteria. Tetraphase has successfully conducted Phase III clinical trials for Xerava, specifically targeting complicated intra-abdominal infections. In addition to Xerava, the company is developing several other candidates, including TP-271 for respiratory diseases linked to bacterial biothreats and TP-6076 for MDR Gram-negative infections, both in Phase I clinical trials. Furthermore, TP-2846 is being explored as a treatment for acute myeloid leukemia. Tetraphase Pharmaceuticals has established a licensing agreement with Everest Medicines Limited to enhance the development and commercialization of Xerava in select regions across Asia. Founded in 2006 and headquartered in Watertown, Massachusetts, Tetraphase operates as a subsidiary of La Jolla Pharmaceutical Company.

BG Medicine, Inc. is a life sciences company dedicated to the development and commercialization of diagnostic products aimed at assisting patients with heart failure and related disorders in the United States. The company offers the BGM Galectin-3 Test, an in vitro diagnostic device that quantifies galectin-3 levels in serum or plasma using an enzyme-linked immunosorbent assay on a microtiter plate platform. Additionally, BG Medicine provides the CardioSCORE Test, a multi-analyte biomarker-based blood test that evaluates the near-term risk of atherothrombotic cardiovascular events, including heart attacks and ischemic strokes. The company has established licensing and commercialization agreements with various healthcare organizations for automated versions of its galectin-3 test. Founded in 2000 and headquartered in Waltham, Massachusetts, BG Medicine was previously known as Beyond Genomics, Inc. before changing its name in 2004.

Agios Pharmaceuticals is a biopharmaceutical company focused on developing targeted therapies in the field of cellular metabolism. It discovers and develops medicines for various indications, including hematologic malignancies, solid tumors, and rare genetic diseases.

Pervasis Therapeutics is a clinical stage biotechnology company focused on developing innovative biologically active therapeutics aimed at enhancing healing and repair processes associated with various diseases. Leveraging its expertise in endothelial biology, the company is advancing novel therapies designed to improve outcomes in common vascular interventions, including arteriovenous access, angioplasties, stents, and bypass grafts. These interventions are critical, as their failure can lead to severe complications and increased healthcare costs. One of the company's key products, PVS-30200, is a matrix-embedded endothelial cell-based therapy that targets and regulates cell stroma, aiming to address vascular injuries across diverse clinical settings. Through its research and development efforts, Pervasis Therapeutics seeks to transform the treatment landscape for serious illnesses related to vascular health.

BIND Therapeutics is a clinical-stage nanomedicine platform company focused on developing innovative targeted and programmable therapeutics known as Accurins. These specialized drug delivery systems are engineered with distinct physical and chemical properties to effectively target specific cells or tissues, concentrating therapeutic agents at the disease site to improve treatment efficacy while reducing adverse effects on healthy tissues. BIND's primary focus is on oncology, with its lead drug candidate, BIND-014, currently undergoing Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer. The company also collaborates with leading biopharmaceutical firms, such as Amgen, Pfizer, and AstraZeneca, to create Accurins utilizing their therapeutic payloads. Through its medicinal nanoengineering platform, BIND Therapeutics aims to advance its own pipeline and forge strategic partnerships in the field of cancer treatment.

Ensemble Discovery is developing a new class of therapeutics - the Ensemblinsâ„¢, orally bioavailable small molecule macrocyclic compounds that have the potential to behave like biologics and can disrupt protein-protein interactions. They have two complementary platforms that provide access to these molecules. Firstly, they use their proprietary DNA-Programmed Chemistryâ„¢ (DPCâ„¢) platform to generate hundreds of thousands of these molecules for rapid screening. Secondly, they have highly developed methods for the synthesis of Ensemblins as discrete molecules using conventional chemistry.

LS9, known as the Renewable Petroleum Company, is a privately-held industrial biotechnology firm based in South San Francisco, California. The company focuses on the development and production of patent-pending UltraClean fuels and sustainable chemicals utilizing synthetic biology. By harnessing advanced industrial synthetic biology techniques, LS9 aims to create renewable petroleum biofuels that serve as eco-friendly alternatives to traditional fossil fuels.

Adnexus, a Bristol-Myers Squibb R&D Company, specializes in the discovery and development of Adnectins, a unique class of targeted biologics. These proteins are engineered to block or stimulate therapeutic targets to combat various diseases, addressing significant medical needs in oncology, immunology, and cardiovascular health. Utilizing a proprietary protein engineering system known as PROfusion™, Adnexus can generate a vast library of over 10 trillion potential Adnectins. This technology enhances the efficiency of identifying candidates with desirable therapeutic properties. Among its product candidates is Angiocept/CT-322, an anti-angiogenesis agent aimed at treating cancer by inhibiting the VEGFR-2 pathway. Since its acquisition by Bristol-Myers Squibb in 2007, Adnexus has further advanced its capabilities in developing innovative medicines to improve patient outcomes.

LS9, known as the Renewable Petroleum Company, is a privately-held industrial biotechnology firm based in South San Francisco, California. The company focuses on the development and production of patent-pending UltraClean fuels and sustainable chemicals utilizing synthetic biology. By harnessing advanced industrial synthetic biology techniques, LS9 aims to create renewable petroleum biofuels that serve as eco-friendly alternatives to traditional fossil fuels.

BIND Therapeutics is a clinical-stage nanomedicine platform company focused on developing innovative targeted and programmable therapeutics known as Accurins. These specialized drug delivery systems are engineered with distinct physical and chemical properties to effectively target specific cells or tissues, concentrating therapeutic agents at the disease site to improve treatment efficacy while reducing adverse effects on healthy tissues. BIND's primary focus is on oncology, with its lead drug candidate, BIND-014, currently undergoing Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer. The company also collaborates with leading biopharmaceutical firms, such as Amgen, Pfizer, and AstraZeneca, to create Accurins utilizing their therapeutic payloads. Through its medicinal nanoengineering platform, BIND Therapeutics aims to advance its own pipeline and forge strategic partnerships in the field of cancer treatment.

Ensemble Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, focused on discovering and developing innovative small molecule therapies for cancer and other serious diseases. The company's pipeline primarily emphasizes immuno-oncology programs, including targets like Indoleamine 2,3-dioxygenase 1 (IDO-1) and Ubiquitin-specific protease 9x. Additionally, Ensemble Therapeutics explores inhibitors of apoptosis proteins such as XIAP and cIAP, as well as Cyclophilins, which play roles in protein folding and cancer progression. The company aims to address drug targets that are typically considered inaccessible with conventional small molecule drugs, offering patients new treatment options.

Codon Devices is a biotechnology company that develops, builds, and supplies synthetic biology products for research. It creates synthetic biological parts and offers a BioLOGIC Engineering Platform that integrates design algorithms with assay and protein engineering to design, discover, and optimize proteins for specific applications. The company also operates a BioFAB Production Platform that manufactures synthetic genes.

Tetraphase Pharmaceuticals, Inc. is a biopharmaceutical company focused on the creation, development, and commercialization of innovative antibiotics aimed at treating serious and life-threatening multidrug-resistant infections. The company's primary product, Xerava, is a synthetic fluorocycline administered intravenously, designed as a first-line empiric monotherapy for multidrug-resistant infections, particularly those caused by MDR Gram-negative bacteria. Tetraphase has successfully conducted Phase III clinical trials for Xerava, specifically targeting complicated intra-abdominal infections. In addition to Xerava, the company is developing several other candidates, including TP-271 for respiratory diseases linked to bacterial biothreats and TP-6076 for MDR Gram-negative infections, both in Phase I clinical trials. Furthermore, TP-2846 is being explored as a treatment for acute myeloid leukemia. Tetraphase Pharmaceuticals has established a licensing agreement with Everest Medicines Limited to enhance the development and commercialization of Xerava in select regions across Asia. Founded in 2006 and headquartered in Watertown, Massachusetts, Tetraphase operates as a subsidiary of La Jolla Pharmaceutical Company.

Morphotek, established in 2000, is a prominent life science company specializing in developing novel biological products to combat cancer, inflammation, and infectious diseases. The company's core technology, morphogenics, was co-invented by its current President and CEO, Dr. Nicholas Nicolaides, during his postgraduate research at Johns Hopkins Medical School. Morphotek focuses on discovering and developing monoclonal antibodies (mAbs) using this proprietary technology to treat various conditions such as ovarian and pancreatic cancers, rheumatoid arthritis, and asthma. The company conducts independent research and clinical development programs for its drug candidates.

Adnexus, a Bristol-Myers Squibb R&D Company, specializes in the discovery and development of Adnectins, a unique class of targeted biologics. These proteins are engineered to block or stimulate therapeutic targets to combat various diseases, addressing significant medical needs in oncology, immunology, and cardiovascular health. Utilizing a proprietary protein engineering system known as PROfusion™, Adnexus can generate a vast library of over 10 trillion potential Adnectins. This technology enhances the efficiency of identifying candidates with desirable therapeutic properties. Among its product candidates is Angiocept/CT-322, an anti-angiogenesis agent aimed at treating cancer by inhibiting the VEGFR-2 pathway. Since its acquisition by Bristol-Myers Squibb in 2007, Adnexus has further advanced its capabilities in developing innovative medicines to improve patient outcomes.

Helicos BioSciences Corporation (Helicos) is a life sciences company, which has developed technology focused on the research, drug discovery and clinical diagnostics markets. Its True Single Molecule Sequencing (tSMS) technology enables rapid analysis of large quantities of genetic material by directly sequencing single molecules of deoxyribonucleic acid (DNA) or single DNA copies of ribonucleic acid (RNA) (cDNA) and its approach of direct sequencing of RNA. Its Helicos Genetic Analysis Platform is designed to obtain sequencing information by repetitively performing a cycle of biochemical reactions on individual DNA or RNA molecules and imaging the results after each cycle. The platform consists of an instrument called the HeliScope Single Molecule Sequencer, an image analysis computer tower called the HeliScope Analysis Engine, associated reagents, which are chemicals used in the sequencing process and disposable supplies.

Epitome Biosystems is a biotechnology company dedicated to enhancing drug discovery and development through innovative protein measurement products and services. The company specializes in the development of technology that measures protein biomarkers and intracellular infrastructure, employing advanced techniques such as antibody microarrays. This approach enables precise measurement of protein biomarkers and intracellular signaling pathways, which are critical for understanding biological processes and advancing therapeutic research. Epitome Biosystems aims to improve productivity in the pharmaceutical industry by providing tools that facilitate more effective drug development and discovery.

T2 Biosystems, Inc. is an in vitro diagnostics company specializing in the rapid detection of pathogens and biomarkers to enhance patient care. The company employs its proprietary T2 Magnetic Resonance technology, which allows for the detection of various pathogens directly from unpurified patient samples, such as whole blood and urine, without the need for extensive sample preparation. T2 Biosystems offers several diagnostic products, including the T2Dx Instrument, which is designed to identify pathogens associated with sepsis and Lyme disease. Its product lineup includes the T2Candida Panel for detecting Candida species, the T2Bacteria Panel for identifying bacterial pathogens, the T2SARS-CoV-2 Panel for COVID-19 testing, and the T2Resistance Panel for detecting antibiotic resistance markers. Founded in 2006 and headquartered in Lexington, Massachusetts, T2 Biosystems aims to improve clinical outcomes and reduce healthcare costs by enabling faster and more accurate diagnostic testing.

Pervasis Therapeutics is a clinical stage biotechnology company focused on developing innovative biologically active therapeutics aimed at enhancing healing and repair processes associated with various diseases. Leveraging its expertise in endothelial biology, the company is advancing novel therapies designed to improve outcomes in common vascular interventions, including arteriovenous access, angioplasties, stents, and bypass grafts. These interventions are critical, as their failure can lead to severe complications and increased healthcare costs. One of the company's key products, PVS-30200, is a matrix-embedded endothelial cell-based therapy that targets and regulates cell stroma, aiming to address vascular injuries across diverse clinical settings. Through its research and development efforts, Pervasis Therapeutics seeks to transform the treatment landscape for serious illnesses related to vascular health.

Codon Devices is a biotechnology company that develops, builds, and supplies synthetic biology products for research. It creates synthetic biological parts and offers a BioLOGIC Engineering Platform that integrates design algorithms with assay and protein engineering to design, discover, and optimize proteins for specific applications. The company also operates a BioFAB Production Platform that manufactures synthetic genes.

Seahorse Bioscience specializes in providing analytical instruments, biomanufacturing systems, and consumable labware for biological research and drug discovery. The company is known for its Seahorse extracellular flux (XF) analyzers, which allow for non-invasive profiling of cellular metabolic activity. These instruments enable researchers to assess key metabolic parameters, such as basal oxygen consumption, glycolysis rates, ATP turnover, and respiratory capacity, thereby facilitating the study of mitochondrial dysfunction. Seahorse Bioscience serves a diverse clientele, including scientists at academic institutions, pharmaceutical and biotech companies, and original equipment manufacturers of assay kits and laboratory instruments.

Pervasis Therapeutics is a clinical stage biotechnology company focused on developing innovative biologically active therapeutics aimed at enhancing healing and repair processes associated with various diseases. Leveraging its expertise in endothelial biology, the company is advancing novel therapies designed to improve outcomes in common vascular interventions, including arteriovenous access, angioplasties, stents, and bypass grafts. These interventions are critical, as their failure can lead to severe complications and increased healthcare costs. One of the company's key products, PVS-30200, is a matrix-embedded endothelial cell-based therapy that targets and regulates cell stroma, aiming to address vascular injuries across diverse clinical settings. Through its research and development efforts, Pervasis Therapeutics seeks to transform the treatment landscape for serious illnesses related to vascular health.

Ensemble Discovery is developing a new class of therapeutics - the Ensemblinsâ„¢, orally bioavailable small molecule macrocyclic compounds that have the potential to behave like biologics and can disrupt protein-protein interactions. They have two complementary platforms that provide access to these molecules. Firstly, they use their proprietary DNA-Programmed Chemistryâ„¢ (DPCâ„¢) platform to generate hundreds of thousands of these molecules for rapid screening. Secondly, they have highly developed methods for the synthesis of Ensemblins as discrete molecules using conventional chemistry.

Pervasis Therapeutics is a clinical stage biotechnology company focused on developing innovative biologically active therapeutics aimed at enhancing healing and repair processes associated with various diseases. Leveraging its expertise in endothelial biology, the company is advancing novel therapies designed to improve outcomes in common vascular interventions, including arteriovenous access, angioplasties, stents, and bypass grafts. These interventions are critical, as their failure can lead to severe complications and increased healthcare costs. One of the company's key products, PVS-30200, is a matrix-embedded endothelial cell-based therapy that targets and regulates cell stroma, aiming to address vascular injuries across diverse clinical settings. Through its research and development efforts, Pervasis Therapeutics seeks to transform the treatment landscape for serious illnesses related to vascular health.

Morphotek, established in 2000, is a prominent life science company specializing in developing novel biological products to combat cancer, inflammation, and infectious diseases. The company's core technology, morphogenics, was co-invented by its current President and CEO, Dr. Nicholas Nicolaides, during his postgraduate research at Johns Hopkins Medical School. Morphotek focuses on discovering and developing monoclonal antibodies (mAbs) using this proprietary technology to treat various conditions such as ovarian and pancreatic cancers, rheumatoid arthritis, and asthma. The company conducts independent research and clinical development programs for its drug candidates.

Celexion, LLC is a bioengineering company based in Cambridge, Massachusetts, founded in 2009. The company specializes in developing platform technologies and products for various sectors, including pharmaceuticals, industrial applications, agriculture, and life sciences research. Celexion offers a range of services that include antibody discovery, scaffold creation, reformatting, affinity maturation, humanization, and metabolic pathway development. Additionally, it provides life science tools and product development services to its partners, leveraging its expertise to support advancements in these fields. As of April 2015, Celexion operates as a subsidiary of Agenus Inc.

It is a biomolecular engineering company focused on conceiving, developing, and fabricating novel biological systems.

Adnexus, a Bristol-Myers Squibb R&D Company, specializes in the discovery and development of Adnectins, a unique class of targeted biologics. These proteins are engineered to block or stimulate therapeutic targets to combat various diseases, addressing significant medical needs in oncology, immunology, and cardiovascular health. Utilizing a proprietary protein engineering system known as PROfusion™, Adnexus can generate a vast library of over 10 trillion potential Adnectins. This technology enhances the efficiency of identifying candidates with desirable therapeutic properties. Among its product candidates is Angiocept/CT-322, an anti-angiogenesis agent aimed at treating cancer by inhibiting the VEGFR-2 pathway. Since its acquisition by Bristol-Myers Squibb in 2007, Adnexus has further advanced its capabilities in developing innovative medicines to improve patient outcomes.

BG Medicine, Inc. is a life sciences company dedicated to the development and commercialization of diagnostic products aimed at assisting patients with heart failure and related disorders in the United States. The company offers the BGM Galectin-3 Test, an in vitro diagnostic device that quantifies galectin-3 levels in serum or plasma using an enzyme-linked immunosorbent assay on a microtiter plate platform. Additionally, BG Medicine provides the CardioSCORE Test, a multi-analyte biomarker-based blood test that evaluates the near-term risk of atherothrombotic cardiovascular events, including heart attacks and ischemic strokes. The company has established licensing and commercialization agreements with various healthcare organizations for automated versions of its galectin-3 test. Founded in 2000 and headquartered in Waltham, Massachusetts, BG Medicine was previously known as Beyond Genomics, Inc. before changing its name in 2004.

Applied Genomic Technology Capital Funds (www.agtcfunds.com) is a new venture capital group focused on investment opportunities enabled by the genomic revolution. AGTC Funds will invest in start-up and early stage companies that apply genomic information and technologies to develop products or services that create significant shareholder value. Formed by NewcoGen Group, in conjunction with OneLiberty Ventures, AGTC Funds' limited partners include both institutional investors and corporations with a strategic interest in genomics. As the first specialty fund focused on this sector, AGTC expects to play a leadership role in selecting, funding and developing new genomics-application companies.

AnVil, Inc., a life sciences discovery company, provides in silico drug discovery and drug development solutions. The company specializes in exploring data sets in DNA microarrays, protein microarrays, cheminformatics, screening, and clinical trial data for pharmaceutical, biotechnology, genomics, and proteomics industries. It combines data mining, statistical analysis, and visualization methods to reveal information in data sets from healthcare and health insurance clients. The company also develops algorithms and tools that support the analysis of data, disease identification, and outcome measure definitions. AnVil, Inc. was formerly known as AnVil Informatics.